文献速递妇科

聚(ADP核糖)聚合酶抑制剂尼拉帕利:毒性管理

The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
PubMed 文献 · Gynecol Oncol · 2018-02-04

尼拉帕利是一种口服PARP抑制剂,已获美国FDA和欧洲EMA批准用于对铂类化疗完全或部分缓解的复发性卵巢癌患者的维持治疗。I期和III期研究显示其在BRCA突变和BRCA野生型癌症中均有活性与获益。毒性包括血液学、胃肠道、疲劳和心血管毒性;基于ENGOT-OV16/NOVA研究分析,基线体重≤77kg和/或基线血小板≤150,000K/uL的患者应考虑起始剂量调整为200mg以降低血液学毒性。

要点

  • 尼拉帕利获批用于复发性卵巢癌铂类化疗缓解后的维持治疗。
  • 基线体重≤77kg和/或血小板≤150,000K/uL者考虑起始剂量200mg。
  • 所有接受尼拉帕利治疗的患者中AML和MDS总体风险为0.9%。

核心结论

  • 尼拉帕利在BRCA突变和BRCA野生型卵巢癌中均有活性与获益,需管理其血液学、胃肠道、疲劳和心血管毒性。

研究设计与样本

  • I期和III期研究评估了尼拉帕利的活性与获益,包括III期ENGOT-OV16/NOVA研究。
  • I期试验确立了尼拉帕利最大耐受剂量为300mg口服每日一次。
  • III期ENGOT-OV16/NOVA研究比较了尼拉帕利维持治疗与安慰剂。

主要发现

  • 尼拉帕利在BRCA突变和BRCA野生型卵巢癌患者中均显示获益。
  • 尼拉帕利的毒性包括血液学毒性(血小板减少、贫血、中性粒细胞减少和白细胞减少)、胃肠道毒性、疲劳和心血管毒性(高血压、心动过速以及心悸)。
  • 所有接受尼拉帕利治疗的患者中急性髓系白血病(AML)和骨髓增生异常综合征(MDS)的总体风险为0.9%。

关键数值与推荐

  • 基于ENGOT-OV16/NOVA研究的近期分析,基线体重≤77kg和/或基线血小板≤150,000K/uL的患者应考虑起始剂量调整为尼拉帕利200mg,以避免显著血液学毒性,尤其是血小板减少。
  • 应监测患者的高血压。

临床怎么用

  • 对基线体重≤77kg和/或基线血小板≤150,000K/uL的患者,考虑起始剂量调整为尼拉帕利200mg以降低血液学毒性风险。
  • 接受尼拉帕利治疗的患者应监测高血压。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Niraparib is an oral poly(ADP ribose) polymerase (PARP) inhibitor that is currently approved by the United States Food and Drug Administration (US FDA) as well as recently approved by the European Medicines Agency (EMA) for the maintenance treatment of women with recurrent ovarian cancer who are in complete or partial response to platinum-based chemotherapy. The mechanisms of action of niraparib include inhibition of PARP enzymatic activity as well as increased formation of PARP-DNA complexes through "trapping" the PARP enzyme on damaged DNA. Phase I and III studies have demonstrated activity and benefit of niraparib in both BRCA mutated (BRCAm) and BRCA wild-type (BRCAwt) cancers. Phase I testing of niraparib established the maximally tolerated dose of 300mg by mouth (PO) daily, and the phase 3 ENGOT-OV16/NOVA study demonstrated the benefit of niraparib maintenance therapy compared to placebo after completion of and response to platinum-based chemotherapy in both BRCAm and BRCAwt ovarian cancer patient populations. Toxicities seen with niraparib include hematologic, gastrointestinal, fatigue, and cardiovascular. Hematologic toxicities include thrombocytopenia, anemia, neutropenia and leukopenia; upfront dose modification to 200mg niraparib for patients with baseline weight of ≤77kg and/or baseline platelets of ≤150,000K/uL should be considered to avoid significant hematologic toxicity, especially thrombocytopenia, based on recent analyses of the ENGOT-OV16/NOVA study. Cardiovascular toxicities include hypertension, tachycardia, as well as palpitations, and patients should be monitored for hypertension. PARP inhibitors have been associated with low risks of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), and the overall risk of AML and MDS is 0.9% of all patients treated with niraparib. Niraparib testing is ongoing in newly diagnosed ovarian cancer patients as maintenance therapy following completion of platinum-based chemotherapy, in BRCAwt cancers as treatment, as well as in combinations with other biologic drugs such as immunotherapy and anti-angiogenic agents.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Moore KN, Mirza MR, Matulonis UA, et al. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Gynecol Oncol. 2018. PMID: 29397193. doi:10.1016/j.ygyno.2018.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。